ReviewFrontiers in reproductive health2022
Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence.
Review in Frontiers in reproductive health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Platelet-rich plasma intracavernosal injections for the treatment of primary organic erectile dysfunction: a systematic review and meta-analysis of contemporary controlled studies.International journal of impotence research · 2024Pooled it
- Efficacy of platelet-rich plasma in the treatment of erectile dysfunction: A meta-analysis of controlled and single-arm trials.PloS one · 2024Pooled it
- Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study.International urology and nephrology · 2025Trial
- Erectile dysfunction and Peyronie's disease: from biologics to nanomedicine-enabled therapies.Sexual medicine · 2026Review
- From Regenerative Mechanisms to Clinical Practice: Current Status, Controversies, and Future Perspectives of Platelet-Rich Plasma in Urology and Sexual Medicine.Journal of clinical medicine · 2026Review
- Erectile dysfunction in dermatology and venereology: From aetiopathogenic mechanisms to practical considerations for dermato-venereologists.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Review
- Atherosclerosis-induced arterial erectile dysfunction: pathogenesis, diagnosis, and therapeutic strategies.Translational andrology and urology · 2025Review
- Association of Sexual Health and Mental Health in Erectile Dysfunction: Expert Opinion From the Indian Context.Cureus · 2025Review
- Clinical efficacy of intracavernous injection of platelet lysate for erectile dysfunction.BMC urology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erectile dysfunction (ED) is one of the commonest disorders in adult males and affects 12-19% of men of reproductive age. Only few studies have evaluated the impact of ED on men and couples with infertility-these studies report higher rates of ED in this sub-group of men compared to the general population, with the prevalence of ED in men diagnosed with male infertility ranging from 6.7 to 61.6%. Nevertheless, ED is considered a rare cause of male infertility, accounting for about 0.4-5% of all causes of male infertility. ED remains a poorly treated condition globally and current therapies, like oral medication, offer only temporary symptomatic relief and do not influence disease progression-patients are potentially on lifelong treatment, with ED worsening over time. In contrast, regenerative medicine may potentially reverse or halt the progression of ED processes. In this article, we review the evidence for intracavernosal injections of platelet-rich plasma (PRP) in the treatment of ED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.